Saturday 17 October 2026
Export ENOV’s income statement to Excel — free account
Enovis Corporation
ENOV Healthcare Medical Devices
Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024. In the quarter to June 2026, revenue grew 3.23%, EPS grew 96.9%, free cash flow grew 815.8% and total debt fell 7.82%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
19.59
0.24
+1.24%
Follow ENOV
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (54.27%) | (55.48%) | (58.40%) | (51.04%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
4 | 4 | 4 | 4 | |
| (25.07%) | (26.12%) | (27.69%) | (27.39%) | ||
ROIC |
(23.55%) | (24.14%) | (25.53%) | (24.01%) | |
Return on Tangible Assets |
(97.48%) | (98.83%) | (106.17%) | (114.78%) | |
Average Days of Receivables |
70.22 | 71.16 | 71.89 | 70.57 | |
Free Cash Flow per Share |
1.11 | 0.63 | 0.35 | 0.40 | |
Free Cash Flow |
63.66 | 35.92 | 19.92 | 22.77 | |
Capital Expenditures |
(206.44) | (206.92) | (197.38) | (194.31) | |
| Other line items | |||||
Cash ROIC |
2.29% | 1.27% | 0.71% | 0.67% | |
Accounts Receivable Turnover |
5.13 | 5.18 | 5.29 | 5.37 | |
Accounts Payable Turnover |
4.40 | 4.48 | 4.92 | 5.21 | |
Inventory Turnover |
1.45 | 1.51 | 1.60 | 1.52 | |
Average Days of Payables |
79.44 | 86.65 | 75.82 | 78.02 | |
Days of Inventory on Hand |
245.77 | 244.41 | 236.27 | 240.90 | |
Tax Rate |
0.03 | 0.03 | 0.02 | 0.03 | |
Research and Development Expense of Revenue |
5.41% | 5.41% | 5.35% | 5.06% | |
Selling, General and Administrative Expense of Revenue |
47.05% | 47.58% | 47.60% | 47.35% | |
Share Based Compensation of Revenue |
1.51% | 1.50% | 1.46% | 1.46% | |
Interest Coverage |
(30.90) | (30.77) | (32.28) | (35.37) | |
Operating CF/Net income |
(0.25) | (0.21) | (0.18) | (0.16) | |
Depreciation/Fixed assets |
2.55 | 2.59 | 2.65 | 3.06 | |
Capex/Depreciation |
(0.15) | (0.15) | (0.15) | (0.13) | |
Revenue per Share |
39.87 | 39.75 | 39.39 | 39.06 | |
Operating CF per Share |
4.69 | 4.24 | 3.81 | 3.80 | |
Capex per Share |
(3.58) | (3.61) | (3.46) | (3.40) | |
Capex to Sales |
0.09 | 0.09 | 0.09 | 0.09 |
Columns are period end dates